Divis Laboratories Q4 FY26 Results: PAT Rs 751 Cr

May 25, 2026
Posted by: Kunal Singla
Category: News

Divis Laboratories Q4 FY26 results were declared on May 24, 2026. The company reported PAT of Rs 751 crore for the quarter ended March 31, 2026, up 13.4% YoY compared to Rs 662 crore in Q4 FY25. Revenue from operations was Rs 2,831 crore, for the quarter ended March 31, 2026. Results are on a Consolidated basis. Divis Laboratories is a Pharmaceuticals and APIs company listed on Indian stock exchanges.

Click Here – Get Free Investment Predictions

Table of Contents

Divis Laboratories Q4 FY26 Financial Highlights

Metric	Q4 FY26 (Rs Cr)	Q4 FY25 (Rs Cr)	YoY Change
Revenue	Rs 2,831 crore	Rs N/A crore	N/A
Net Profit	751	662	+13.4%
Basis	Consolidated

Note: Divis Laboratories Q4 FY26 results declared May 24, 2026. Data sourced from BSE/NSE filings. Verify from audited statements before investment decisions.

Divis Laboratories Q4 FY26 Performance Analysis

The Divis Laboratories Q4 FY26 results reflect the company’s financial performance during the January to March 2026 quarter. The company delivered results in line with its sector performance trends. Divis Laboratories operates in the Pharmaceuticals and APIs sector, which benefits from India’s strong macroeconomic environment with GDP growth above 6.5% in FY26.

Revenue of Rs 2,831 crore was for the quarter ended March 31, 2026. Steady revenue reflects consistent business delivery.

Screen the best stocks on the Univest Screener.

Key Factors Driving Divis Laboratories Q4 FY26 Results

Revenue and Operational Performance

Revenue of Rs 2,831 crore in Divis Laboratories Q4 FY26 was for the quarter ended March 31, 2026. Stable revenue reflects consistent operational delivery. The Q4 FY26 quarter is the fiscal year-end period, characterised by strong order execution and year-end activity across India Inc.

Profitability and Margin Trends

The Divis Laboratories Q4 FY26 PAT of Rs 751 crore up 13.4% YoY. Stable profitability reflects consistent operational execution in the Pharmaceuticals and APIs sector.

India Macro Environment

India’s macroeconomic environment in Q4 FY26 was supportive with GDP growth above 6.5%, government capital expenditure of Rs 11.21 lakh crore budgeted for FY27, and resilient domestic consumption. The Reserve Bank of India’s accommodative stance supported credit conditions. For Divis Laboratories operating in the Pharmaceuticals and APIs sector, these structural tailwinds provided a constructive operating backdrop.

FY27 Outlook

Following the business results, management guidance on FY27 revenue growth, margin improvement roadmap, capital allocation plans, and demand pipeline visibility will be key investor watchpoints. The Pharmaceuticals and APIs sector continues to benefit from India’s long-term structural growth story. Consistent revenue growth and margin expansion remain the strategic priorities.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on the firm

What is Divis Laboratories Q4 FY26 net profit?

Ans. Divis Laboratories Q4 FY26 PAT of Rs 751 crore, up 13.4% YoY from Rs 662 crore in Q4 FY25. Results declared May 24, 2026, on a Consolidated basis. Verify from BSE/NSE audited filings.

What is Divis Laboratories Q4 FY26 revenue?

Ans. Divis Laboratories Q4 FY26 revenue was Rs 2,831 crore, for the quarter ended March 31, 2026. Verify complete financials from BSE/NSE.

When were Divis Laboratories Q4 FY26 results declared?

Ans. Divis Laboratories Q4 FY26 results were declared on May 24, 2026, at the board of directors meeting approving audited Q4 and full-year FY26 financial statements.

Is Divis Laboratories a good investment after Q4 FY26?

Ans. Investment decisions require individual assessment of fundamentals, valuation, and risk tolerance. This article is educational only. Consult a SEBI-registered financial advisor before investing in Divis Laboratories.

Investments in securities are subject to market risk. This content is for educational purposes only. Verify all figures from BSE/NSE filings. Consult a SEBI-registered financial advisor.

News Q4 Results

Author: Kunal Singla

Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.